Generate Biomedicines, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Generate Biomedicines, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $414.00K, a 168.83% increase year-over-year.
- Generate Biomedicines, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $3.22M, a 566.05% increase year-over-year.
- Generate Biomedicines, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $154.00K.
- Generate Biomedicines, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-03-31 was $483.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $414.00K 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $3.22M 10-Q · filed 2026-08-06 | |
| 2025-06-30 | $154.00K 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $483.00K 10-Q · filed 2026-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |